Category: Pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with a median survival of 2-5 years from diagnosis [1.5.7]. This raises a critical question for patients and clinicians: **Does pirfenidone reverse fibrosis**, or does it only slow the decline?

While the prognosis for idiopathic pulmonary fibrosis (IPF) has long been abysmal, with limited treatment options, a growing body of research suggests a surprising new avenue. Recent studies have investigated the potential of the common diabetes medication, metformin, and its ability to not only slow the progression of fibrosis but potentially reverse established disease.

According to clinical trials, a significant number of patients on Esbriet experienced fatigue, with some studies reporting incidence rates as high as 26% compared to placebo groups. It's crucial for patients to understand if and **does Esbriet cause fatigue** and how to manage this side effect effectively.